VYxeoS Liposomal Italian Observational Study iN the Real Practice
← catalyst calendarSponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Advice Pharma S.r.l..
Phase
—
Status
Completed
Study type
Observational
Enrollment
113actual
Sites
24
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-07 | actual | When the study began enrolling |
| Primary completion | 2025-10-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-23 | actual | The whole study's end, after follow-up |
| First posted | 2023-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Therapy-Related Acute Myeloid Leukemia
Intervention
- Drug: Vyxeos liposomal — also filed as JZP351, CPX-351
Primary outcome
what the primary-completion date above is the date OFPercentage of participants showing CR/CRi/CRh without MRD at the end of treatment
measured Up to 24 months
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed